Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Short nutrition boost before cancer surgery: does it help?

NCT ID NCT01023412

Disease control Sponsor: Société des Produits Nestlé (SPN) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving well-nourished people with gastrointestinal cancer a special nutrition drink for 3 days before surgery could reduce complications and shorten hospital stays. The trial was stopped early, so results are limited. It involved 107 adults with stomach, pancreas, or bowel cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

107 people

The number who actually took part.

Start date

Jan 2006

Finished

May 2008

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with GI cancer (stomach, pancreas, small and large bowel and rectum) histologically proven * Well nourished patients as defined by a total score of \<3 on the nutritional screening tool NRS-2002 (46) (Appendix III) * Patients who are \>= 18 years of age; * Patients who have signed a written Informed Consent (Appendix I) prior to admission to the study; * Patients who have an ECOG performance status of 0, 1 or 2 (Appendix II). * Patients able to orally consume 750 mL or more of liquid a day prior to surgery Exclusion Criteria: * Patients who have co-morbid conditions, uncontrolled metabolic conditions or psychiatric conditions that might make tolerance or evaluation of the feeding formula difficult; * Patients who are pregnant; * Patients with cardiac failure as defined by the Goldman classification class\>3 * Patients with respiratory failure (FEV\<0.8l/sec) * Patients with renal failure (Cr \>= 3mg/dl or dialysis patients) * Patients with hepatic dysfunction (Child \>A) * Patients suffering from an intestinal obstruction or ileum * Patients with an Hb level of \<=8 g/dL experiencing gastrointestinal hemorrhaging * Patients with HIV, HCV, HBV * Patients requiring immunosuppression treatments * Patients undergoing emergency surgery * Other patients determined by a study investigator to be inappropriate for enrolment in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal cancer

Contacts and locations

Locations

  • Kantonsspital Aarau

    Aarau, 5001, Switzerland

  • Kantonsspital Baden

    Baden, 5404, Switzerland

  • Kantonsspital Liestal

    Liestal, 4410, Switzerland

  • Kantonsspital Schaffausen

    Schaffhausen, 8208, Switzerland

  • Kantonsspital St.Gallen

    Sankt Gallen, 9000, Switzerland

  • Lindenhof-Spital

    Bern, 3012, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.